MX377816B - Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos. - Google Patents
Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos.Info
- Publication number
- MX377816B MX377816B MX2016004742A MX2016004742A MX377816B MX 377816 B MX377816 B MX 377816B MX 2016004742 A MX2016004742 A MX 2016004742A MX 2016004742 A MX2016004742 A MX 2016004742A MX 377816 B MX377816 B MX 377816B
- Authority
- MX
- Mexico
- Prior art keywords
- same
- ketone derivatives
- preparing
- pyridil
- pharmaceutical application
- Prior art date
Links
- -1 PYRIDIL KETONE Chemical class 0.000 title 1
- 150000002576 ketones Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a derivados de cetona pirídicos, el método de preparación de los mismos, y la aplicación farmacéutica de los mismos. Específicamente la presente invención se refiere a derivados cetona pirídicos representados por la general (I) y las sales de los mismos, método de preparación de los mismos y usos de los mismos como inhibidores de MEK y especialmente como agentes terapéuticos para cáncer, donde las definiciones de los sustituyentes en la fórmula general (I) son las mismas como la definición en la descripción. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310512377 | 2013-10-25 | ||
| PCT/CN2014/085976 WO2015058589A1 (zh) | 2013-10-25 | 2014-09-05 | 吡啶酮类衍生物、其制备方法及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016004742A MX2016004742A (es) | 2016-12-09 |
| MX377816B true MX377816B (es) | 2025-03-11 |
Family
ID=52992223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004742A MX377816B (es) | 2013-10-25 | 2014-09-05 | Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9914703B2 (es) |
| EP (1) | EP3061747B1 (es) |
| JP (1) | JP6403172B2 (es) |
| KR (1) | KR102222569B1 (es) |
| CN (1) | CN104936945B (es) |
| AU (1) | AU2014339527B2 (es) |
| BR (1) | BR112016007396B1 (es) |
| CA (1) | CA2927635C (es) |
| ES (1) | ES2868450T3 (es) |
| MX (1) | MX377816B (es) |
| PL (1) | PL3061747T3 (es) |
| PT (1) | PT3061747T (es) |
| RU (1) | RU2667892C2 (es) |
| TW (1) | TWI662026B (es) |
| WO (1) | WO2015058589A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017018580A2 (pt) * | 2015-03-27 | 2018-04-24 | Jiangsu Hengrui Medicine Co., Ltd. | p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal |
| CN104892499B (zh) * | 2015-06-26 | 2017-07-21 | 江西省科学院应用化学研究所 | 一种2‑吡啶酮类衍生物的合成方法 |
| CA3041561A1 (en) * | 2016-11-25 | 2018-05-31 | Jiangsu Hengrui Medicine Co., Ltd. | Pyridone derivative pharmaceutical composition and preparation method thereof |
| TW201821408A (zh) * | 2016-12-01 | 2018-06-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種吡啶酮類衍生物的製備方法及其中間體 |
| CN108314645A (zh) * | 2017-01-18 | 2018-07-24 | 上海映诺济生物科技有限公司 | 一类具有抗细胞增殖活性的化合物、制备方法和用途 |
| RU2742234C1 (ru) | 2017-06-23 | 2021-02-03 | Систоун Фармасьютикалс | Кумариноподобное циклическое соединение в качестве ингибитора мек и его применение |
| WO2020125747A1 (zh) * | 2018-12-21 | 2020-06-25 | 基石药业(苏州)有限公司 | 一种mek抑制剂的晶型、无定形及其应用 |
| WO2020156162A1 (zh) * | 2019-01-29 | 2020-08-06 | 贝达药业股份有限公司 | Mek抑制剂及其在医药上的应用 |
| CN111514140B (zh) * | 2019-02-01 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 一种mek抑制剂联合雄激素受体拮抗剂在制备治疗肿瘤药物中的用途 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| TW202114994A (zh) * | 2019-07-29 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種1,6-二氫吡啶-3-甲醯胺衍生物的製備方法 |
| WO2021047573A1 (zh) * | 2019-09-11 | 2021-03-18 | 江苏恒瑞医药股份有限公司 | 一种mek抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤的药物中的用途 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AR121078A1 (es) * | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| CN111848613B (zh) * | 2020-08-11 | 2021-09-24 | 山东大学 | 一种二芳基嘧啶骈吡啶酮类衍生物及其制备方法与应用 |
| LT4122926T (lt) | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
| KR20230026288A (ko) * | 2021-08-17 | 2023-02-24 | 주식회사 카나프테라퓨틱스 | Sos1 억제제 및 이의 용도 |
| CN114605408B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用 |
| CN119768393A (zh) * | 2022-05-25 | 2025-04-04 | 医肯纳肿瘤学公司 | Mek抑制剂和其用途 |
| EP4788839A1 (en) | 2023-10-03 | 2026-08-12 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| CN120441478A (zh) * | 2024-02-07 | 2025-08-08 | 成都赜灵生物医药科技有限公司 | 一种六元内酰胺类化合物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002354575A1 (en) * | 2001-07-12 | 2003-01-29 | Bristol-Myers Squibb Pharma Company | Tetrahydropurinones as corticotropin releasing factor |
| US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| KR100883289B1 (ko) * | 2004-06-11 | 2009-02-11 | 니뽄 다바코 산교 가부시키가이샤 | 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2h-피리도[2,3-d]피리미딘 유도체 및 관련 화합물 |
| TWI441637B (zh) * | 2005-05-18 | 2014-06-21 | Array Biopharma Inc | Mek雜環抑制劑及其使用方法 |
| ES2354916T3 (es) * | 2006-02-22 | 2011-03-21 | F. Hoffmann-La Roche Ag | Inhibidores de quinasa basados en la hidantoína. |
| US7612212B2 (en) | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| JP5615274B2 (ja) | 2008-07-01 | 2014-10-29 | ジェネンテック, インコーポレイテッド | Mekキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法 |
| CN102134218A (zh) | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
| US20120238599A1 (en) * | 2011-03-17 | 2012-09-20 | Chemizon, A Division Of Optomagic Co., Ltd. | Heterocyclic compounds as mek inhibitors |
| WO2012162293A1 (en) | 2011-05-23 | 2012-11-29 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mek inhibitors |
| MA37405A1 (fr) | 2012-03-14 | 2016-03-31 | Lupin Ltd | Composés hétérocyclyle |
-
2014
- 2014-09-05 EP EP14854930.6A patent/EP3061747B1/en active Active
- 2014-09-05 MX MX2016004742A patent/MX377816B/es unknown
- 2014-09-05 US US15/030,125 patent/US9914703B2/en not_active Expired - Fee Related
- 2014-09-05 CA CA2927635A patent/CA2927635C/en not_active Expired - Fee Related
- 2014-09-05 PT PT148549306T patent/PT3061747T/pt unknown
- 2014-09-05 JP JP2016518444A patent/JP6403172B2/ja not_active Expired - Fee Related
- 2014-09-05 ES ES14854930T patent/ES2868450T3/es active Active
- 2014-09-05 AU AU2014339527A patent/AU2014339527B2/en not_active Ceased
- 2014-09-05 WO PCT/CN2014/085976 patent/WO2015058589A1/zh not_active Ceased
- 2014-09-05 KR KR1020167012819A patent/KR102222569B1/ko not_active Expired - Fee Related
- 2014-09-05 CN CN201480003661.8A patent/CN104936945B/zh active Active
- 2014-09-05 PL PL14854930T patent/PL3061747T3/pl unknown
- 2014-09-05 BR BR112016007396-7A patent/BR112016007396B1/pt not_active IP Right Cessation
- 2014-09-05 RU RU2016118753A patent/RU2667892C2/ru active
- 2014-09-25 TW TW103133170A patent/TWI662026B/zh not_active IP Right Cessation
-
2017
- 2017-09-28 US US15/719,138 patent/US10064848B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015058589A1 (zh) | 2015-04-30 |
| CA2927635C (en) | 2021-07-20 |
| RU2016118753A3 (es) | 2018-05-25 |
| EP3061747B1 (en) | 2021-04-07 |
| US20180016236A1 (en) | 2018-01-18 |
| PT3061747T (pt) | 2021-05-04 |
| AU2014339527B2 (en) | 2018-07-19 |
| TWI662026B (zh) | 2019-06-11 |
| RU2667892C2 (ru) | 2018-09-25 |
| CN104936945A (zh) | 2015-09-23 |
| PL3061747T3 (pl) | 2021-07-19 |
| BR112016007396A2 (pt) | 2017-08-01 |
| US9914703B2 (en) | 2018-03-13 |
| AU2014339527A1 (en) | 2016-05-12 |
| US10064848B2 (en) | 2018-09-04 |
| US20160244410A1 (en) | 2016-08-25 |
| TW201518278A (zh) | 2015-05-16 |
| KR102222569B1 (ko) | 2021-03-05 |
| JP6403172B2 (ja) | 2018-10-10 |
| JP2016534027A (ja) | 2016-11-04 |
| KR20160074554A (ko) | 2016-06-28 |
| EP3061747A1 (en) | 2016-08-31 |
| MX2016004742A (es) | 2016-12-09 |
| CA2927635A1 (en) | 2015-04-30 |
| CN104936945B (zh) | 2017-11-03 |
| RU2016118753A (ru) | 2017-11-29 |
| EP3061747A4 (en) | 2017-05-10 |
| HK1212980A1 (zh) | 2016-06-24 |
| BR112016007396B1 (pt) | 2021-01-19 |
| ES2868450T3 (es) | 2021-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016007396A2 (pt) | derivados de cetona pirídicos, método de preparação dos mesmos e aplicação farmacêutica dos mesmos | |
| JOP20180099B1 (ar) | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| DOP2014000203A (es) | Compuestos de heterociclilo | |
| CR20150045A (es) | Inhibidores de hepatitis c | |
| CY1120515T1 (el) | Παραγωγο κυκλοαλκυλικο οξεος, μεθοδος παρασκευης και φαρμακευτικη εφαρμογη αυτου | |
| EA201401292A2 (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
| BR112016008468A2 (pt) | Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer | |
| MX376271B (es) | Compuestos heterocíclicos y usos de los mismos. | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| BR112015019627A2 (pt) | amidas heterocíclicas como inibidores de quinases | |
| MX382991B (es) | Inhibidores de la arginina metiltransferasa y usos de los mismos. | |
| BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
| CR20150470A (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
| TR201902709T4 (tr) | Mek inhibitörleri olarak bileşikler ve bileşimler. | |
| UA113470C2 (xx) | Піримідинові та піридинові сполуки та їх застосування | |
| MX2015009479A (es) | Compuestos y metodos para tratar infecciones bacterianas. | |
| TW201613904A (en) | Pyridone derivatives containing tetrahydropyranylmethyl group | |
| CO7350640A2 (es) | Compuestos diméricos | |
| MX382347B (es) | Derivados de piridincarboxamida, su método de preparación y sus usos farmacéuticos. | |
| MX380546B (es) | Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos. | |
| UY36110A (es) | Inhibidores de quinasa relacionados con tropomiosina | |
| EA201500931A1 (ru) | Производные пиридин-4-ила | |
| UA111333C2 (uk) | Спосіб одержання l-аргінінової солі периндроприлу | |
| CY1120142T1 (el) | Ενωσεις αζετιδινυλοξυφαινυλοπυρρολiδινης |